BCM
DYN icon

Bridgeway Capital Management’s Dyne Therapeutics DYN Stock Holding History

Bridgeway Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
+50,000
New +$930K 0.02% 716
2023
Q2 		– Sell
-10,400
Closed -$120K – 1405
2023
Q1 		$120K Hold
10,400
– – ﹤0.01% 1202
2022
Q4 		$121K Hold
10,400
– – ﹤0.01% 1193
2022
Q3 		$132K Sell
10,400
-6,000
-37% -$68.8K ﹤0.01% 1221
2022
Q2 		$113K Buy
+16,400
New +$113K ﹤0.01% 1205

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Bridgeway Capital Management's DYN Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 50,000 shares worth $1.11M. The stake represents 0.02% of the portfolio and ranks #716 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in DYN as recently as Q1 2023.

Bridgeway Capital Management first reported a position in DYN in Q2 2022 and has held it in 5 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Bridgeway Capital Management held 50,000 shares of Dyne Therapeutics worth $1.11M as of Q2 2026.
  • Dyne Therapeutics was a new Bridgeway Capital Management position in Q2 2026.
  • Dyne Therapeutics made up 0.02% of Bridgeway Capital Management's portfolio in Q2 2026, its #716 holding.
  • Bridgeway Capital Management first reported a position in Dyne Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.